10x Genomics Appoints Two New Members to Its Board of Directors

10x Genomics announced the appointment of Dr. Ansuman Satpathy and Mr. Joseph Gilliam to its Board of Directors as Class III directors, effective October 28, 2026. The appointments add significant scientific expertise in genomics and immunology, as well as financial and operational leadership experience from the medical technology industry.

Key Details

• New Directors: Dr. Ansuman Satpathy, an Associate Professor at Stanford University and co-founder of several life sciences companies, and Mr. Joseph Gilliam, President and COO of Glaukos Corporation.
• Committee Appointment: Mr. Gilliam was appointed Chair of the Audit Committee, effective October 30, 2026, for which he will receive an additional annual retainer of $25,000.
• Director Compensation: Each new director will receive a $60,000 annual cash retainer, a one-time restricted stock unit (RSU) grant valued at $400,000, and an annual RSU grant valued at $215,000.
• Terms: The directors' terms are set to expire at the company's 2028 annual meeting of stockholders.